BMO Capital analyst Evan Seigerman raised the firm’s price target on Terns Pharmaceuticals (TERN) to $22 from $15 and keeps an Outperform rating on the shares. The firm increased its probability of success for TERN-701 to 70% and peak unadjusted sales estimate to $3.7B following today’s abstract data. Terns shares may be undervalued with products like Novartis’s Scemblix estimated to reach well over $3B in peak sales, the analyst tells investors in a research note. BMO sees additional upside in the stock even after Monday’s 80% rally.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals price target raised to $35 from $28 at Jefferies
- Enliven being 20% down on Terns news ‘makes no sense,’ says Mizuho
- Midday Fly By: AWS in deal with OpenAI, Kimberly-Clark to buy Kenvue
- William Blair upgrades Terns Pharmaceuticals after ‘impressive’ data
- Terns Pharmaceuticals upgraded to Outperform from Market Perform at William Blair